SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,112,050. The last known price of Bitcoin is 63,437.21016941 USD and is down -7.02 over the last 24 hours. It is currently trading on 12780 active market(s) with $45,086,253,428.50 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins sharp selloff and break below short-term support levels dominate the discussion, with traders worried about further declines and possible cascading liquidations. The community is split between bearish calls for more downside and investors viewing the drop as capitulation or a buying opportunity; proposed causes such as institutional selling and broader market weakness remain speculation.

Ethereum (ETH) is a cryptocurrency . Ethereum has a current supply of 122,218,624.4003947. The last known price of Ethereum is 1,739.90377069 USD and is down -9.84 over the last 24 hours. It is currently trading on 14359 active market(s) with $18,820,901,710.98 traded over the last 24 hours. More information can be found at https://www.ethereum.org/.

Ethereum

Ethereum is caught in a broad crypto selloff, with Bitcoin weakness and forced liquidations adding to pressure. Traders are divided between treating the drop as capitulation and buying the dip, and expecting further losses; some also speculate that macro uncertainty and competition for capital are weighing on crypto.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Bitcoins sharp selloff is weighing on Strategy shares, with traders treating MSTR as a leveraged Bitcoin proxy and debating whether further crypto losses could pressure its holdings and financing strategy. The community is also focused on the announced MSCI index removal and potential passive selling, while some traders view the decline as a buying opportunity.

Dogecoin (DOGE) is a cryptocurrency . Users are able to generate DOGE through the process of mining. Dogecoin has a current supply of 156,752,062,860.16806072. The last known price of Dogecoin is 0.05689686 USD and is down -11.89 over the last 24 hours. It is currently trading on 1545 active market(s) with $1,128,721,930.78 traded over the last 24 hours. More information can be found at http://dogecoin.com/.

Dogecoin

Dogecoin is drawing attention amid a steep decline alongside broader crypto weakness, with traders pointing to fresh multi-year lows and questioning whether buyers will step in. The discussion is largely bearish, though some see the selloff as a buying opportunity and expect a rebound.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 0.92173784 USD and is down -8.73 over the last 24 hours. It is currently trading on 1896 active market(s) with $4,059,642,828.82 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRP is drawing attention amid a sharp crypto-wide selloff, with traders pointing to Bitcoin weakness and leveraged liquidations as pressure on the token. The community is split between expecting further declines and viewing the drop as a buying opportunity, with many expressing concern that XRP has fallen below the $1 level.

Solana (SOL) is a cryptocurrency launched in 2020. Solana has a current supply of 637,554,569.48929238 with 591,573,607.37721086 in circulation. The last known price of Solana is 69.50906472 USD and is down -10.60 over the last 24 hours. It is currently trading on 1189 active market(s) with $4,775,978,662.51 traded over the last 24 hours. More information can be found at https://solana.com.

Solana

Solana is drawing attention amid a sharp crypto-wide selloff, with traders focused on its steep decline and whether the weakness signals further downside. Bearish calls about capitulation and lower support levels compete with dip-buying and staking advocates who view the drop as an accumulation opportunity.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Norwalk, CT.

BitMine Immersion Technologies Inc

Ethereum and broader crypto weakness are weighing on BMNR, whose large ETH treasury makes its shares sensitive to the tokens decline. Traders are split between expecting a rebound and criticizing the stocks losses, Tom Lees bullish calls, and the pace of buybacks.

Avalanche (AVAX) is a cryptocurrency launched in 2020. Avalanche has a current supply of 471,438,169.1160568 with 446,436,169.1160568 in circulation. The last known price of Avalanche is 6.99518175 USD and is down -15.00 over the last 24 hours. It is currently trading on 1135 active market(s) with $402,139,637.32 traded over the last 24 hours. More information can be found at https://avax.network/.

Avalanche

AVAX is drawing attention after a sharp selloff alongside Bitcoin and broader altcoins, with traders pointing to its pronounced losses and weak rebounds. The reaction is largely bearish and frustrated, though some see the decline as a buying opportunity; several say the move lacks a clear AVAX-specific catalyst.

Stellar (XLM) is a cryptocurrency launched in 2014. Stellar has a current supply of 50,001,786,837.39707 with 35,407,563,191.01116 in circulation. The last known price of Stellar is 0.13466341 USD and is down -7.69 over the last 24 hours. It is currently trading on 849 active market(s) with $286,159,144.84 traded over the last 24 hours. More information can be found at https://www.stellar.org.

Stellar Lumens

XLM is drawing attention amid a steep selloff alongside broader crypto weakness, with traders debating whether the decline will continue or offer a buying opportunity. Some holders point to Stellars tokenization and institutional-adoption prospects, including DTCC-related developments, but others question whether those developments will translate into demand for XLM.

Hedera (HBAR) is a cryptocurrency launched in 2017. Hedera has a current supply of 50,000,000,000 with 44,327,139,454.06818907 in circulation. The last known price of Hedera is 0.05610846 USD and is down -8.30 over the last 24 hours. It is currently trading on 469 active market(s) with $93,154,645.45 traded over the last 24 hours. More information can be found at https://www.hedera.com/.

Hedera Hashgraph

HBAR is drawing attention amid a sharp decline alongside a broader crypto selloff, with traders debating whether the drop reflects market weakness or deeper concerns about Hederas tokenomics and adoption. Reactions are split between holders accumulating the dip and frustrated sellers calling the project a poor investment.

statis crypto Watchlist

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rigels Q3 results and the sharp post-report selloff dominate discussion, with traders weighing an earnings miss against record product sales, VEPPANUs promising early launch, and the companys revenue outlook. Views are split between frustration over the market reaction and optimism about VEPPANUs growth potential and upcoming R289 data.

Rigel to Present at the Jefferies Global Healthcare Conference in London

Rigel to Present at the Jefferies Global Healthcare Conference in London Rigel to Present at the Jefferies Global Healthcare Conference in LondonPR NewswireSOUTH SAN FRANCISCO, Calif., Nov. 10, 2026 SOUTH SAN FRANCISCO, Calif., Nov. 10, 2026 /PRNewswire/ -- Rigel Pharmaceuticals,Inc. (Nasdaq...

Rigel Pharmaceuticals (RIGL) Misses Q3 Earnings Estimates

Rigel (RIGL) delivered earnings and revenue surprises of -25.29% and +3.35%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Rigel Reports Third Quarter 2026 Financial Results

Rigel Reports Third Quarter 2026 Financial Results Rigel Reports Third Quarter 2026 Financial ResultsPR NewswireSOUTH SAN FRANCISCO, Calif., Nov. 5, 2026 Third quarter 2026 total revenues of $80.9 million, including net product sales of $72.3 million and contract revenues from collaborations of...

Rigel Announces Oral Presentation of Phase 1b Data for R289 in Patients with Lower-Risk MDS at the 68th American Society of Hematology Annual Meeting and Exposition

Rigel Announces Oral Presentation of Phase 1b Data for R289 in Patients with Lower-Risk MDS at the 68th American Society of Hematology Annual Meeting and Exposition Rigel Announces Oral Presentation of Phase 1b Data for R289 in Patients with Lower-Risk MDS at the 68th American Society of Hematology...

United Therapeutics (UTHR) Q3 Earnings Miss Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of -2.39% and +6.28%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results

Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial ResultsPR NewswireSOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 /PRNewswire/ -- Rigel...

Rigel Highlights New GAVRETO (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026

Rigel Highlights New GAVRETO (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026 Rigel Highlights New GAVRETO (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026PR NewswireSOUTH SAN...

Reasons Why Investors Should Consider Betting on Arvinas Stock

ARVN's first FDA-approved PROTAC degrader validates its technology, while a diverse pipeline targeting cancer and neurological disorders offers further growth potential.

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)PR NewswireSOUTH SAN FRANCISCO, Calif., Oct. 2, 2026SOUTH SAN FRANCISCO, Calif., Oct. 2, 2026 /PRNewswire...

EVP & Chief Financial Officer At Rigel Pharmaceuticals Exercises Options Worth $123K

A large exercise of company stock options by Dean Schorno, EVP & Chief Financial Officer at Rigel Pharmaceuticals (NASDAQ:RIGL) was disclosed in a new SEC filing on September 3, as part of an insider exercise.
Whatread more...

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

Neutral Sentiment

<ul class="summary-bullets"><li>Rigel will develop, manufacture, and commercialize Vepdegestrant, which will be sold under the brand name Veppanu.</li><li>Vepannu, developed by Arvinas and Pfizer, received FDA approval earlier this month.</li><li>Arvinas and Pfizer will receive $70 million upfront and an additional $15 million upon completion of certain transition activities.</li></ul>Shares of Rigel Pharmaceuticals, Inc (RIGL) surged more than 15% on Tuesday after investors welcomed a potential growth opportunity tied to the company’s newly signed global licensing deal with Arvinas (ARVS) and Pfizer (PFE) for a breast cancer treatment.According to Koyfin data, short interest in <a href="https://stocktwits.com/symbol/RIGL">RIGL</a> climbed to 22.3% of the float as of May 12, up sharply from 15.5% at the beginning of the year, marking its highest level ever. The company has roughly 18.5 million outstanding shares.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://app.koyfin.com/charts/g/eq-stzcug"><img src="https://news.stocktwits-cdn.com/Rigel_jpg_90c3024bd7.webp" alt="Rigel.jpg"></a>Source: Koyfin<h2 class="st-heading-2">Veppanu To Drive RIGL’s Revenue Growth</h2>Under the agreement, Rigel will develop, manufacture, and commercialize Vepdegestrant, which will be sold under the brand name Veppanu. The drug is the only FDA-approved oral PROteolysis TArgeting Chimera (PROTAC) therapy, a new class of medicines designed to target and break down disease-causing proteins.Arvinas and Pfizer will receive $70 million upfront and an additional $15 million upon completion of certain transition activities. The companies could also receive up to $320 million in future milestone payments.Rigel said Veppanu will become its fourth commercial product and a key driver of future revenue growth as it expands its cancer treatment portfolio.“Veppanu is expected to contribute strong revenue growth in our expanding commercial portfolio, and we believe it has the potential to become a meaningful driver of long-term growth for Rigel,” said Raul Rodriguez, Rigel’s president and CEO.<h2 class="st-heading-2">Vepannu’s Phase 3 Data Shows 43% Fall In Disease Progression Risk</h2>The drug, developed by Arvinas and Pfizer, received FDA<a href="https://stocktwits.com/news-articles/markets/equity/arvn-stock-gains-fda-approval-breast-cancer-drug-pfizer/cZQVgmpReen">&nbsp;approval</a> earlier this month. The regulatory clearance was supported by a Phase 3 study showing that Veppanu reduced the risk of disease progression or death by 43% compared with the comparator cancer drug, Fulvestrant. Patients treated with Veppanu had a median progression-free survival of five months, compared with 2.1 months for Fulvestrant.Following the FDA approval, Arvinas announced plans to partner with a third party to support the drug’s commercial rollout. Veppanu received Fast Track designation from the FDA in 2024, followed by the agency’s acceptance of its New Drug Application (NDA) for review last August.<h2 class="st-heading-2">RIGL Bulls Eyes $50</h2>Retail sentiment for RIGL shares on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘extremely high’ message volumes.One user expects the stock to climb to $50, a 40% upside from current levels, stating Rigel is no longer “just a company managing a future patent cliff” but is a “growing commercial oncology company.”<stembedurl>https://stocktwits.com/ExtraRun123/message/653075404</stembedurl>Another user called the deal a “potential game-changer.”<stembedurl>https://stocktwits.com/Ou8mycookie/message/653059707</stembedurl>The stock has gained more than 14% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/nvda-stock-has-gained-nearly-16-in-a-month-but-wall-street-sees-further-upside/cZXXhJWReiX">NVDA Stock Has Gained Nearly 16% In A Month – But Wall Street Sees Further Upside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on technology background. MRAM and HPAI stocks surged in overnight trading (Image source: Getty Images)

RIGL Stock Jumps 15%, Short Interest Surges To Record High – Why Is Retail Eyeing A Further 40% Upside?

Rigel Pharmaceuticals signed a global licensing deal with Arvinas and Pfizer for an advanced breast cancer treatment.

Equity

Arvinas Inc

Pfizer Inc

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	$1.05	--	--	N/A
Q3 '26	$0.92	$0.65	-29.41%	MISSED
Q2 '26	$0.09	$0.88	903.88%	BEAT
Q1 '26	$0.80	$0.44	-44.67%	MISSED
Q4 '25	$1.20	$13.54	1026.96%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

RIGL Earnings

Latest Earnings Results: Q3 '26

Historical Earnings